Insider Name | Buy/Sell | Company Name | Ticker | Amount | Shares Change | |||
---|---|---|---|---|---|---|---|---|
Jan 29, 2025 | Jan 30, 2025 | Dolan Matthew Vincent EVP Strategy Corporate Dev | Sell | Dexcom Inc | DXCM | $86.91 | $102,820 | -2.74% |
May 15, 2024 | May 16, 2024 | Dolan Matthew Vincent EVP Strategy Corporate Dev | Sell | Dexcom Inc | DXCM | $126.58 | $306,703 | -5.70% |
Apr 15, 2024 | Apr 16, 2024 | Dolan Matthew Vincent EVP Strategy Corporate Dev | Sell | Dexcom Inc | DXCM | $137.81 | $274,242 | -4.49% |
Mar 15, 2024 | Mar 19, 2024 | Dolan Matthew Vincent EVP Strategy Corp Dev | Sell | Dexcom Inc | DXCM | $130.21 | $547,259 | -8.65% |
Mar 12, 2024 | Mar 14, 2024 | Dolan Matthew Vincent EVP Strategy Corporate | Sell | Dexcom Inc | DXCM | $134.41 | $901,896 | -12.14% |
Sep 01, 2023 | Sep 01, 2023 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sell | Dexcom Inc | DXCM | $102.32 | $5,730 | -0.17% |
Mar 16, 2023 | Mar 17, 2023 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sell | Dexcom Inc | DXCM | $115 | $264,845 | -6.42% |
Mar 13, 2023 | Mar 14, 2023 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sell | Dexcom Inc | DXCM | $106.27 | $661,956 | -14.80% |
Mar 06, 2023 | Mar 07, 2023 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sell | Dexcom Inc | DXCM | $114.4 | $25,854 | -0.84% |
Sep 01, 2022 | Sep 06, 2022 | Dolan Matthew Vincent SVP Corporate Strategy-Develop | Sell | Dexcom Inc | DXCM | $81.63 | $408 | -0.02% |
Mar 15, 2022 | Mar 17, 2022 | Dolan Matthew Vincent SVP Corporate Development | Sell | Dexcom Inc | DXCM | $424.68 | $928,359 | -24.78% |